Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lebrikizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lebrikizumab overview
Lebrikizumab (Ebglyss) is a recombinant human IgG4 monoclonal antibody. Ebglyss is formulated as injectable solution for subcutaneous route of administration. Ebglyss is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy.
Lebrikizumab (RG-3637, RO-5490255, MILR-1444A, PRO-301444, TNX-650) is under development for the treatment of persistant moderate to severe atopic dermatitis, perennial allergic rhinitis, chronic rhinosinusitis, nasal polyps. It is administered by subcutaneous route. The drug candidate is an interleukin (IL)-13 antibody. It was also under development for idiopathic pulmonary fibrosis, severe asthma and chronic obstructive pulmonary disease.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company and a provider of in-vitro diagnostics as well as a supplier of transformative innovative solutions across major disease areas. It provides drugs for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers and pharmacists. Roche is headquartered in Basel, Switzerland.
For a complete picture of Lebrikizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
